S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

XBiotech Stock Forecast, Price & News

+0.46 (+3.83%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
59,386 shs
Average Volume
82,267 shs
Market Capitalization
$379.08 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBiotech logo

About XBiotech

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$40 thousand
Book Value
$9.02 per share


Net Income
$-11.22 million
Pretax Margin




Free Float
Market Cap
$379.08 million

Company Calendar

Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.50 out of 5 stars

Medical Sector

1076th out of 1,394 stocks

Pharmaceutical Preparations Industry

509th out of 674 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

XBiotech (NASDAQ:XBIT) Frequently Asked Questions

How has XBiotech's stock been impacted by COVID-19 (Coronavirus)?

XBiotech's stock was trading at $10.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XBIT stock has increased by 16.3% and is now trading at $12.47.
View which stocks have been most impacted by COVID-19

When is XBiotech's next earnings date?

XBiotech is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for XBiotech

How often does XBiotech pay dividends? What is the dividend yield for XBiotech?

XBiotech announced a dividend on Tuesday, July 6th. Stockholders of record on Friday, July 16th will be paid a dividend of $2.50 per share on Friday, July 23rd. The ex-dividend date is Thursday, July 15th.
View XBiotech's dividend history

Who are XBiotech's key executives?

XBiotech's management team includes the following people:
  • John Simard, Chairman, President & Chief Executive Officer
  • Ashley Otero, Vice President-Clinical Operations
  • Queena Han, Secretary, VP-Finance & Human Resources
  • Sushma Shivaswamy, Chief Scientific Officer
  • Mark Ziats, Medical Director

What is John Simard's approval rating as XBiotech's CEO?

20 employees have rated XBiotech CEO John Simard on Glassdoor.com. John Simard has an approval rating of 58% among XBiotech's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Square (SQ).

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.03%), Oracle Investment Management Inc. (1.15%), Geode Capital Management LLC (1.01%), Credit Suisse AG (0.45%), Bank of New York Mellon Corp (0.19%) and Goldman Sachs Group Inc. (0.19%). Company insiders that own XBiotech stock include John Simard, Queena Han, Street Financial SA Bay, Sushma Shivaswamy and W Thorpe Mckenzie.
View institutional ownership trends for XBiotech

Which major investors are selling XBiotech stock?

XBIT stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, and Credit Suisse AG. Company insiders that have sold XBiotech company stock in the last year include John Simard, and Street Financial SA Bay.
View insider buying and selling activity for XBiotech
or view top insider-selling stocks.

Which major investors are buying XBiotech stock?

XBIT stock was acquired by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Goldman Sachs Group Inc., BlackRock Inc., Millennium Management LLC, SG Americas Securities LLC, Dimensional Fund Advisors LP, Geode Capital Management LLC, and PNC Financial Services Group Inc..
View insider buying and selling activity for XBiotech
or or view top insider-buying stocks.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $12.47.

How much money does XBiotech make?

XBiotech has a market capitalization of $379.08 million and generates $40 thousand in revenue each year. The biopharmaceutical company earns $-11.22 million in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does XBiotech have?

XBiotech employs 91 workers across the globe.

What is XBiotech's official website?

The official website for XBiotech is www.xbiotech.com.

Where are XBiotech's headquarters?

XBiotech is headquartered at 5217 Winnebago Ln, AUSTIN TX, 78744.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at (512) 386-2900, via email at [email protected], or via fax at 512-386-5505.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.